Ascentage Pharma Group International (NASDAQ:AAPG) Research Coverage Started at Truist Financial

Truist Financial began coverage on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a research note released on Monday morning, MarketBeat reports. The firm issued a buy rating and a $51.00 price objective on the stock.

A number of other analysts have also recently weighed in on the stock. BTIG Research initiated coverage on shares of Ascentage Pharma Group International in a report on Monday, November 10th. They issued a “buy” rating and a $50.00 price target on the stock. Piper Sandler assumed coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 target price for the company. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $49.67.

Ascentage Pharma Group International Price Performance

Shares of NASDAQ AAPG opened at $32.12 on Monday. Ascentage Pharma Group International has a 1-year low of $16.50 and a 1-year high of $48.45. The business has a fifty day moving average price of $35.21 and a 200 day moving average price of $36.09. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54.

Institutional Trading of Ascentage Pharma Group International

Large investors have recently bought and sold shares of the stock. Monashee Investment Management LLC acquired a new stake in shares of Ascentage Pharma Group International during the first quarter worth $3,511,000. Tema Etfs LLC acquired a new position in shares of Ascentage Pharma Group International in the 2nd quarter valued at $610,000. XY Capital Ltd raised its stake in Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after acquiring an additional 12,530 shares during the last quarter. UBS Group AG lifted its position in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares during the period. Finally, Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International during the second quarter worth about $391,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.